Literature DB >> 20596764

Which beta-blocker is most effective in heart failure?

Willem J Remme1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20596764     DOI： 10.1007/s10557-010-6247-7

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN： 0920-3206            Impact factor:   3.727


× No keyword cloud information.
  9 in total

1.  Novel carvedilol analogues that suppress store-overload-induced Ca2+ release.

Authors:  Chris D Smith; Aixia Wang; Kannan Vembaiyan; Jingqun Zhang; Cuihong Xie; Qiang Zhou; Guogen Wu; S R Wayne Chen; Thomas G Back
Journal:  J Med Chem       Date:  2013-11-05       Impact factor: 7.446

2.  Carvedilol and its new analogs suppress arrhythmogenic store overload-induced Ca2+ release.

Authors:  Qiang Zhou; Jianmin Xiao; Dawei Jiang; Ruiwu Wang; Kannan Vembaiyan; Aixia Wang; Chris D Smith; Cuihong Xie; Wenqian Chen; Jingqun Zhang; Xixi Tian; Peter P Jones; Xiaowei Zhong; Ang Guo; Haiyan Chen; Lin Zhang; Weizhong Zhu; Dongmei Yang; Xiaodong Li; Ju Chen; Anne M Gillis; Henry J Duff; Heping Cheng; Arthur M Feldman; Long-Sheng Song; Michael Fill; Thomas G Back; S R Wayne Chen
Journal:  Nat Med       Date:  2011-07-10       Impact factor: 53.440

3.  Effects of β-blocker therapy on electrocardiographic and echocardiographic characteristics of left ventricular noncompaction.

Authors:  Jin Li; Jennifer Franke; Regina Pribe-Wolferts; Benjamin Meder; Philipp Ehlermann; Derliz Mereles; Florian Andre; Mohamed Assem Abdelrazek; Constanze Merten; Patrick A Schweizer; Rüdiger Becker; Hugo A Katus; Dierk Thomas
Journal:  Clin Res Cardiol       Date:  2014-10-21       Impact factor: 5.460

4.  Exploring the kinetic selectivity of drugs targeting the β1 -adrenoceptor.

Authors:  David A Sykes; Mireia Jiménez-Rosés; John Reilly; Robin A Fairhurst; Steven J Charlton; Dmitry B Veprintsev
Journal:  Pharmacol Res Perspect       Date:  2022-08

5.  Non-β-blocking R-carvedilol enantiomer suppresses Ca2+ waves and stress-induced ventricular tachyarrhythmia without lowering heart rate or blood pressure.

Authors:  Jingqun Zhang; Qiang Zhou; Chris D Smith; Haiyan Chen; Zhen Tan; Biyi Chen; Alma Nani; Guogen Wu; Long-Sheng Song; Michael Fill; Thomas G Back; S R Wayne Chen
Journal:  Biochem J       Date:  2015-07-08       Impact factor: 3.857

6.  Comparison of free-radical inhibiting antioxidant properties of carvedilol and its phenolic metabolites.

Authors:  Thomas C Malig; Mitchell R Ashkin; Austin L Burman; Manuel Barday; Belinda J M Heyne; Thomas G Back
Journal:  Medchemcomm       Date:  2017-01-30       Impact factor: 3.597

7.  Cardiac resynchronization in mild heart failure: all issues resolved? Editorial to "Cardiac resynchronization therapy in patients with mild heart failure: a systematic review and meta-analysis of randomized controlled trials" by Ronghui Tu et al.

Authors:  Alexander H Maass
Journal:  Cardiovasc Drugs Ther       Date:  2011-08       Impact factor: 3.727

8.  Carvedilol and nebivolol improve left ventricular systolic functions in patients with non-ischemic heart failure.

Authors:  Mustafa Karabacak; Abdullah Doğan; Şenol Tayyar; Mehmet Özaydın; Doğan Erdoğan
Journal:  Anatol J Cardiol       Date:  2014-04-08       Impact factor: 1.596

9.  Carvedilol Selectively Stimulates βArrestin2-Dependent SERCA2a Activity in Cardiomyocytes to Augment Contractility.

Authors:  Jennifer Maning; Victoria L Desimine; Celina M Pollard; Jennifer Ghandour; Anastasios Lymperopoulos
Journal:  Int J Mol Sci       Date:  2022-09-26       Impact factor: 6.208
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.